Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy
| Autor: | Wun-Jae Kim, Bup Wan Kim, Seock Hwan Choi, T.G. Kwon, Tae-Hwan Kim, Yun-Sok Ha, Eun Sang Yoo, Seok Jung Yun, Young Suk Kwon |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty Urology medicine.medical_treatment 030232 urology & nephrology 03 medical and health sciences Postoperative Complications 0302 clinical medicine Erectile Dysfunction Risk Factors Sexual medicine Republic of Korea medicine Humans Potency Aged Prostatectomy Sulfonamides Udenafil business.industry Hazard ratio Prostatic Neoplasms Recovery of Function Middle Aged Phosphodiesterase 5 Inhibitors Prognosis medicine.disease Pyrimidines Treatment Outcome Erectile dysfunction Sexual dysfunction 030220 oncology & carcinogenesis Peyronie's disease medicine.symptom business medicine.drug |
| Zdroj: | International Journal of Impotence Research. 28:25-30 |
| ISSN: | 1476-5489 0955-9930 |
| Popis: | Udenafil is a selective phosphodiesterase type 5 inhibitor made available in recent years for the treatment of erectile dysfunction. Herein, we evaluated independent predictors of potency recovery in radical prostatectomy (RP) patients who underwent penile rehabilitation with udenafil 50 mg. One hundred and forty-three men who underwent RP were enrolled in a penile rehabilitation program using udenafil 50 mg every other day. The rate of regained potency in the study group was significantly higher compared with the recovery rate seen in patients who were not part of the penile rehabilitation program (41.3% vs 13.0%; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink